Oncolytics Biotech Inc.

NasdaqCM:ONCY Stock Report

Market Cap: US$97.5m

Oncolytics Biotech Dividends and Buybacks

Dividend criteria checks 0/6

Oncolytics Biotech does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-18.9%

Buyback Yield

Total Shareholder Yield-18.9%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha • Apr 25

Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths

Summary Oncolytics is narrowing Pelareorep development toward anal cancer and metastatic colorectal cancer, making its bull case more concrete. Pelareorep may turn “cold” tumors “hot,” potentially improving chemotherapy and checkpoint inhibitor responses across GI cancers. CRC data showed an unusually high 33% ORR versus 6%-11% historical SoC. This is why it received the FDA’s Fast Track designation. SCAC data showed encouraging response rates and complete responses. ONCY scheduled discussions with the FDA for a single-arm registrational pathway. I reckon ONCY’s dilution and clinical trial risks remain significant. Yet, the upcoming ER updates could help reframe ONCY around clearer regulatory timelines. Read the full article on Seeking Alpha
Analysis Article • Sep 03

Is Oncolytics Biotech (NASDAQ:ONCY) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 11

Oncolytics Biotech: Continuing To Justify The Negativity

Summary Oncolytics Biotech's main asset, pelareorep, shows mixed results in trials, with no definitive efficacy signals and ongoing financial struggles threatening operations. The GOBLET trial in pancreatic cancer continues, but key data readouts are not expected until late 2025, adding uncertainty. ONCY's financial situation is dire, with cash runway only into Q3 2025, raising serious concerns about their ability to fund operations. Given the high risk, low market cap, and lack of clear efficacy, I maintain a "Sell" rating and advise against investing in ONCY. Read the full article on Seeking Alpha

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ONCY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ONCY's dividend payments have been increasing.

Dividend Yield vs Market

Oncolytics Biotech Dividend Yield vs Market
How does ONCY dividend yield compare to the market?
SegmentDividend Yield
Company (ONCY)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.5%
Analyst forecast (ONCY) (up to 3 years)n/a

Notable Dividend: Unable to evaluate ONCY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ONCY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ONCY's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ONCY has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 17:30
End of Day Share Price 2026/06/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncolytics Biotech Inc. is covered by 19 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeCantor Fitzgerald Canada Corporation
Wang ChongEdison Investment Research
Patrick TrucchioH.C. Wainwright & Co.